Therapeutic plasma exchange for fibrinogen-associated hyperviscosity: results of the COVID-19 PLasma EXchange (COPLEX) randomized controlled trial
Journal of Thrombosis and Haemostasis · 2025
DOI: 10.1016/j.jtha.2024.12.021 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025. Verfasst von Cheryl L Maier und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Emory School of Medicine, Atlanta, Georgia, USA. Electronic address: clmaier@emory.edu. Hauptthemen laut MEDLINE: COVID-19, Plasma Exchange, Fibrinogen, Blood Viscosity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Therapeutic plasma exchange (TPE) is the primary intervention for treating symptomatic hyperviscosity from hypergammaglobulinemia, yet its efficacy for treating hyperviscosity related to hyperfibrinogenemia is unclear. OBJECTIVES: Define the safety and efficacy of TPE for critically ill COVID-19 patients with elevated blood viscosity from hyperfibrinogenemia. METHODS: We performed a prospective randomized controlled trial in critically ill COVID-19 patients in a single US healthcare system. Patients with hyperfibrinogenemia (>800 mg/dL) or elevated plasma viscosity (2.3-3.5 centipoise [cP]) were randomized to receive TPE on 2 consecutive days or continued standard of care (SOC). RESULTS: Twenty participants were enrolled, with 10 receiving TPE and 10 receiving SOC alone. Mean (±SEM) plasma viscosity decreased significantly from 2.35 cP (±0.12) to 1.61 cP (±0.03) in the TPE group and was unchanged in the SOC group (2.47 cP [±0.11] to 2.47 cP [±0.15]). Mean fibrinogen decreased from 934.0 mg/dL (±25.1) to 359.1 mg/dL (±22.5) after TPE vs from 859.6 mg/dL (±57.6) to 807.3 mg/dL (±63.1) in SOC. There was no significant difference in 28-day all-cause mortality between groups, with 2 deaths in the TPE cohort and 5 deaths in the SOC cohort (P = .13). No serious safety events related to TPE were reported. TPE significantly decreased biomarkers of inflammation (erythrocyte sedimentation rate and C-reactive protein) and endothelial activation (von Willebrand factor and factor VIII) but not hemostatic activation (prothrombin fragment 1.2, thrombin-antithrombin complex, and fibrin monomer) or immunoglobulin (IgG and IgM) levels. CONCLUSION: TPE is safe and effective for normalizing elevated blood viscosity from hyperfibrinogenemia in COVID-19 patients. Additional studies are needed to determine the impact of TPE on overall patient outcomes, including in those with non-COVID-19 conditions associated with hyperfibrinogenemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Emory School of Medicine, Atlanta, Georgia, USA. Electronic address: clmaier@emory.edu.
- Department of Pathology and Laboratory Medicine, Emory School of Medicine, Atlanta, Georgia, USA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Pharmaceutical Services, Emory Healthcare, Atlanta, Georgia, USA.
- Department of Medicine, Emory School of Medicine, Atlanta, Georgia, USA; Departments of Epidemiology and Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
- Department of Medicine, Emory School of Medicine, Atlanta, Georgia, USA.
- Department of Hematology and Medical Oncology, Emory School of Medicine, Atlanta, Georgia, USA.
Förderung
- NHLBI NIH HHS
Zitieren
APA
Maier, C. L., Nakahara, H., Barker, N. A., Auld, S. C., Truong, A. D., Friend, S., Caridi-Scheible, M., Connor, M., Gaddh, M., Cobb, J., Polly, D. M., Guarner, J., Powell, C., Kempton, C. L., Daniels, L., Wynn, A. T., Sniecinski, R., Duncan, A., Roback, J., …, & Stowell, S. R. (2025). Therapeutic plasma exchange for fibrinogen-associated hyperviscosity: results of the COVID-19 PLasma EXchange (COPLEX) randomized controlled trial. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.12.021
Vancouver
Maier CL, Nakahara H, Barker NA, Auld SC, Truong AD, Friend S, et al. Therapeutic plasma exchange for fibrinogen-associated hyperviscosity: results of the COVID-19 PLasma EXchange (COPLEX) randomized controlled trial. Journal of Thrombosis and Haemostasis. 2025. doi:10.1016/j.jtha.2024.12.021
BibTeX
@article{Maier2025,
author = {Maier, Cheryl L and Nakahara, Hirotomo and Barker, Nicholas A and Auld, Sara C and Truong, Alexander D and Friend, Sarah and Caridi-Scheible, Mark and Connor, Michael and Gaddh, Manila and Cobb, Jason and Polly, Derek M and Guarner, Jeannette and Powell, Cindy and Kempton, Christine L and Daniels, Lisa and Wynn, A Thanushi and Sniecinski, Roman and Duncan, Alexander and Roback, John and Masud, Tahsun and Conlon, Shaun and Wade, Jenna and Wong, Andrew and Verkerke, Hans and Zerra, Patricia E and Butler, Hailly and Sullivan, H Cliff and Easley, Kirk A and Josephson, Cassandra D and Stowell, Sean R},
title = {Therapeutic plasma exchange for fibrinogen-associated hyperviscosity: results of the COVID-19 PLasma EXchange (COPLEX) randomized controlled trial},
journal = {Journal of Thrombosis and Haemostasis},
year = {2025},
doi = {10.1016/j.jtha.2024.12.021}
}
EUVIMED